SCHEMBL737639

SCHEMBL737639

Nc1ccc(OC2CCN(C3CCC3)CC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 20/20 0.63
KCNH2 Q12809 4/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4464014 0.97 HRH3 (0.68) HRH3KCNH2
SCHEMBL17533980 0.95 HRH3 (0.58) HRH3KCNH2
SCHEMBL4468194 0.93 HRH3 (0.58) HRH3KCNH2
SCHEMBL18284038 0.85 HRH3 (0.51) HRH3KCNH2
SCHEMBL2822372 0.85 HRH3 (0.61) HRH3KCNH2
SCHEMBL16712653 0.85 HRH3 (0.61) HRH3KCNH2
SCHEMBL12484261 0.84 HRH3 (0.57) HRH3KCNH2
SCHEMBL737096 0.82 HRH1 (0.54) HRH3KCNH2
SCHEMBL2005027 0.82 HRH3 (0.58) HRH3KCNH2
SCHEMBL10187265 0.81 PARP10 (0.60) HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3180334-B1 PROCESS FOR LARGE SCALE PRODUCTION OF N-[4-(1- CYCLOBUTYL PIPERIDIN-4-YLOXY) PHENYL]-2-(MORPHOLIN-4-YL) ACET AMIDE DIHYDROCHLORIDE SUVEN LIFE SCIENCES LTD (IN) 2018-09-26 EP claimed
US-20090306375-A1 Process for production of 4(3H)-quinazolinone derivative MSD K.K. (JP) 2009-12-10 US claimed
EP-1900733-A1 PROCESS FOR PRODUCTION OF 4(3H)-QUINAZOLINONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-03-19 EP claimed
US-20260048068-A1 PHENYLUREA DERIVATIVES AND THEIR PHARMACEUTICAL USES HANGZHOU BIO SINCERITY PHARMA TECH CO LTD (CN) 2026-02-19 US disclosed
EP-4488263-A2 PHENYLUREA DERIVATIVE AND PHARMACEUTICAL USE THEREOF Hangzhou Bio-Sincerity Pharma-tech Co., Ltd. (CN) 2025-01-08 EP disclosed
US-12172980-B2 Compounds as neuronal histamine receptor-3 antagonists and uses thereof XWPharma Ltd. (KY) 2024-12-24 US disclosed
CN-116693446-A Phenylurea derivative and medical application thereof 杭州百诚医药科技股份有限公司 2023-09-05 CN disclosed
EP-3856719-B1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF XWPHARMA LTD (KY) 2023-06-07 EP disclosed
EP-3856719-B1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF XWPHARMA LTD (KY) 2023-06-07 EP disclosed
US-20220380339-A1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF XWPharma Ltd. (KY) 2022-12-01 US disclosed
US-20220380339-A1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF XWPharma Ltd. (KY) 2022-12-01 US disclosed
US-7521455-B2 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO. LTD. (JP) 2009-04-21 US disclosed
CN-101351459-A Method for producing 4(3H)-quinazolinone derivative BANYU PHARMA CO LTD (JP) 2009-01-21 CN disclosed
EP-1900733-A1 PROCESS FOR PRODUCTION OF 4(3H)-QUINAZOLINONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-03-19 EP disclosed
EP-1900733-A1 PROCESS FOR PRODUCTION OF 4(3H)-QUINAZOLINONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-03-19 EP disclosed
EP-1892241-A1 NOVEL PIPERIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-02-27 EP disclosed
WO-2007004735-A1 METHOD FOR PRODUCING 4(3H)-QUINAZOLINONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-01-11 WO disclosed
WO-2006132424-A1 PROCESS FOR PRODUCTION OF 4(3H)-QUINAZOLINONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-12-14 WO disclosed
EP-1717230-A1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-02 EP disclosed
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380339-A1 COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF HRH3, HRH4, HRH2 HRH3 1/4885KCNH2 763/4885
US-12172980-B2 Compounds as neuronal histamine receptor-3 antagonists and uses thereof HRH3, HRH4, HRH2 HRH3 1/4885KCNH2 499/4885
US-20260048068-A1 PHENYLUREA DERIVATIVES AND THEIR PHARMACEUTICAL USES HRH3, HRH2, HRH4 HRH3 1/4885KCNH2 250/4885
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative HRH4, HRH2, HRH3 HRH3 3/4885KCNH2 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.